Effectiveness of regorafenib in second-line therapy for advanced hepatocellular carcinoma: A systematic review and meta-analysis.

Medicine (Baltimore) · 2025 · PMC11771663 · PMID 39854748

Europe PMC DOI

hedged sentence

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

showed a trendP = .06so close (0.05 < p ≤ 0.1)

A 2017 meta-analysis by Kim et al [ 28 ] found that second-line targeted therapy, such as regorafenib, significantly improved progression time ( P < .0001) and showed a trend towards improved OS ( P = .06).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.